1. Search Result
Search Result
Results for "

CPI

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123419

    Histone Demethylase Cancer
    CPI-4203 is a potent KDM5A inhibitor with an IC50 of 250 nM. CPI-4203 is competitive with 2-oxoglutarate (2-OG). CPI-4203 is structurally related to CPI-455 (HY-100421) but is less potent .
    CPI-4203
  • HY-100376

    TNF Receptor Apoptosis Infection Neurological Disease
    CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases .
    CPI-1189
  • HY-136285

    Histone Acetyltransferase Cancer
    CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    CPI-1612
  • HY-100421
    CPI-455
    5 Publications Verification

    Histone Demethylase Cancer
    CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
    CPI-455
  • HY-15846
    CPI-203
    4 Publications Verification

    Epigenetic Reader Domain Apoptosis Cancer
    CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay).
    CPI-203
  • HY-15453
    Devimistat
    5+ Cited Publications

    CPI-613

    Apoptosis Mitochondrial Metabolism Cancer
    Devimistat (CPI-613) is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells .
    Devimistat
  • HY-134899

    Histone Methyltransferase Cancer
    CPI-1328 is an EZH2 inhibitor with a Ki value of 63 fM.
    CPI-1328
  • HY-111085

    Histone Methyltransferase Cancer
    CPI-905 is a potent, selective, and cell-active EZH2 inhibitor .
    CPI-905
  • HY-100421A

    Histone Demethylase Cancer
    CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
    CPI-455 hydrochloride
  • HY-159777

    E3 Ligase Ligand-Linker Conjugates Cancer
    CPI-203-PEG5-Alkyne is a conjugate of E3 ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .
    CPI-203-PEG5-Alkyne
  • HY-P99181

    CPI-006

    CD73 Infection Inflammation/Immunology Cancer
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells .
    Mupadolimab
  • HY-120196

    Epigenetic Reader Domain Cancer
    CPI703, a BRD inhibitor, binds with residues in domain1 of 5DBM complex .
    CPI703
  • HY-12863

    CPI-0610

    Epigenetic Reader Domain Cancer
    Pelabresib (CPI-0610) is a potent, selective, orally active and cell-active BET inhibitor. Pelabresib inhibits BRD4-BD1 with an IC50 of 39 nM, and with an EC50 value of 0.18 μM for MYC .
    Pelabresib
  • HY-100482
    CPI-637
    Maximum Cited Publications
    11 Publications Verification

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    CPI-637 is a selective and potent CBP/EP300 bromodomain inhibitor with IC50 values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, EP300 and BRD4 BD-1, respectively, and an EC50 of 0.3 μM for CBP .
    CPI-637
  • HY-145602

    CPI-0209

    Histone Methyltransferase Cancer
    Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies .
    Tulmimetostat
  • HY-101978
    Ciforadenant
    5 Publications Verification

    CPI-444; V81444

    Adenosine Receptor Cancer
    Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .
    Ciforadenant
  • HY-15453S

    CPI-613-d10

    Isotope-Labeled Compounds Cancer
    Devimistat-d10 (CPI-613-d10) is the deuterium-labeled Devimistat (HY-15453) .
    Devimistat-d10
  • HY-150298

    CPI-818

    Itk Inflammation/Immunology Cancer
    Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
    Soquelitinib
  • HY-102024

    CPI-444 analog

    Adenosine Receptor Neurological Disease Cancer
    A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A2A receptor and A1 receptor with Ki values of 4 and 264 nM, respectively .
    A2A receptor antagonist 1
  • HY-15846A

    Others Cancer
    (Rac)-CPI-203 is a racemate of CPI-203 (HY-15846) (BET bromodomain inhibitor)
    (Rac)-CPI-203
  • HY-145386

    Others Cancer
    (S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    (S,S)-CPI-1612
  • HY-136285A

    Others Cancer
    (R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    (R,R)-CPI-1612
  • HY-109706

    Bacterial Fungal Infection
    (Rac)-CPI-098 shows antibacterial activity. (Rac)-CPI-098 exhibits superior anti-fungal activity against Monascus ruber, better activity against Aspergillus fumigates, good activity against Aspergillus niger and Aspergillus parasites and moderate activity against Candida albicans .
    (Rac)-CPI-098
  • HY-161250

    PROTACs Cancer
    Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC50 of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .
    Pomalidomide-NH-PEG6-amide-C2-CPI-1612
  • HY-129379

    ADC Cytotoxin Cancer
    DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component .
    DC0-NH2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: